(Q36584377)

15 August 2017

1 reference

title

Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes (English)

1 reference

15 August 2017

1 reference

cervix uterine cancer

1 reference

4

Sue J Goldie

1 reference

15 August 2017

Geoffrey P Garnett

1

1 reference

15 August 2017

Jane J Kim

series ordinal

2

1 reference

15 August 2017

Katherine French

series ordinal

3

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 August 2006

1 reference

15 August 2017

1 reference

15 August 2017

volume

24 Suppl 3

1 reference

15 August 2017

page(s)

S3/178-86

1 reference

Evaluating human papillomavirus vaccination programs

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.116

Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.116

Role of herd immunity in determining the effect of vaccines against sexually transmitted disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.116

Hepatitis B vaccination: how to reach risk groups

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.116

Quantitative investigations of different vaccination policies for the control of congenital rubella syndrome (CRS) in the United Kingdom

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.116

Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.116

A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.116

An introduction to mathematical models in sexually transmitted disease epidemiology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.116

Measuring sexual behaviour: methodological challenges in survey research.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.116

Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.116

Potential health and economic impact of adding a human papillomavirus vaccine to screening programs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.116

Potential impact of low efficacy HIV-1 vaccines in populations with high rates of infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.116

The potential epidemiological impact of a genital herpes vaccine for women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.116

The theoretical population-level impact of a prophylactic human papilloma virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.116

Vaccination against human papillomaviruses shows great promise

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.116

10.1016/J.VACCINE.2006.05.116

7 January 2021

Identifiers

DOI

1 reference

15 August 2017

1 reference